A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2001
10/18/2001	WO2001077113A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
10/18/2001	WO2001077079A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001076694A1 Inhibitors of prenyl-protein transferase
10/18/2001	WO2001076649A1 An injectable bone mineral substitute material
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076632A1 Formulation for the prevention of cardiovascular disease
10/18/2001	WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	WO2001076619A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
10/18/2001	WO2001076615A2 Cxcr4 agonist treatment of hematopoietic cells
10/18/2001	WO2001076602A1 Apomorphine derivatives and methods for their use
10/18/2001	WO2001076601A2 Pharmaceutical compositions comprising salmeterol and ipratropium
10/18/2001	WO2001076586A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	WO2001076579A1 Treatment of skin damage using olive oil polyphenols
10/18/2001	WO2001076577A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	WO2001076576A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001	WO2001076575A2 The treatment of respiratory diseases
10/18/2001	WO2001076574A2 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076570A2 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
10/18/2001	WO2001076569A2 An improved pt(iv) antitumor agent
10/18/2001	WO2001076567A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	WO2001076522A1 Maintaining abstinence after detoxification from opiate addiction
10/18/2001	WO2001076370A2 Anthelmintic combinations
10/18/2001	WO2001076361A1 Animal and cell models for type ii diabetes and their use
10/18/2001	WO2001038352A3 Methods of inhibiting metastasis
10/18/2001	WO2001030342A9 Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
10/18/2001	WO2001026737A3 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
10/18/2001	WO2001026604A3 Hair and scalp treatment method and recipes for application of this method
10/18/2001	WO2001024817A3 Pharmaceutical compositions of fibrinolytic agent
10/18/2001	WO2001023540A3 P-glycoproteins and uses thereof
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2001022090A9 Method for identifying compounds useful in the therapy of bone disorders
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2000078299A3 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
10/18/2001	WO2000069898A8 Molecular interactions in allergy cells
10/18/2001	WO2000057837A9 Compositions and methods for effecting the levels of cholesterol
10/18/2001	WO2000047130A9 Injectable collagen-based system for delivery of cells or therapeutic agents
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	WO2000035436A3 Treatment of arthritis with mek inhibitors
10/18/2001	WO2000020041A9 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
10/18/2001	US20010032339 Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
10/18/2001	US20010031873 Drug delivery, antitumor agents
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031779 Methods and materials for treating and preventing inflammation of mucosal tissue
10/18/2001	US20010031773 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, HIV and Kaposi sarcoma, as viricides and anticarcinogenic agents
10/18/2001	US20010031770 Pyridoxal analogues and methods of treatment
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031752 Administered as anorexigenic agents, dietetics, antidiabetics and for enhancing lipid metabolism
10/18/2001	US20010031750 Administering an analgesic of an inhibitor of cyclic guanosine monophosphate dependent protein kinase such as rp-8-((4-chlorophenyl)thio)-guanosine 3',5'-cyclic monophosphothioate triethylamine
10/18/2001	US20010031744 Using mixture of plant extract and angiogenesis inhibitor
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031737 Unit dosage forms for the treatment of herpes simplex
10/18/2001	US20010031733 Compound B as angiogenic agent in combination with human growth factors
10/18/2001	US20010031722 Methods and reagents for facilitating transcription
10/18/2001	US20010031474 Chimeric neuropeptide Y receptors
10/18/2001	US20010031285 Interleukin-4 production inhibitors
10/18/2001	US20010031281 Compositon to enhance permeation of topical skin agents
10/18/2001	US20010031274 Biodegradable polymer
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	US20010031039 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus
10/18/2001	DE10007234A1 Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems Peptide and nucleic acid coding for determining diagnosis and treatment of diseases of the nervous system
10/18/2001	CA2414652A1 Animal and cell models for type ii diabetes and their use
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2405895A1 Combination of organic compounds
10/18/2001	CA2405793A1 Combination of organic compounds
10/18/2001	CA2405730A1 Serine-threonine kinase
10/18/2001	CA2405568A1 Prion-binding peptidic ligands and methods of using same
10/18/2001	CA2405419A1 Apomorphine derivatives and methods for their use
10/18/2001	CA2405360A1 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	CA2405311A1 Multiprotein-complexes comprising a nmda receptor and uses thereof
10/18/2001	CA2405307A1 Application of substances acting as cascade inhibitors of the raf/mek/erk signaling cascade for the production of a drug against infections by dna and rna viruses
10/18/2001	CA2405306A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	CA2405181A1 Human pyruvate dehydrogenese phosphatase
10/18/2001	CA2405142A1 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001	CA2405117A1 Specific inhibitors of ribosome recycling factor (rrf)
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2405083A1 New bromodomain protein
10/18/2001	CA2404988A1 Listeria monocytogenes genome, polypeptides and uses
10/18/2001	CA2404971A1 Human protein kinases and protein kinase-like enzymes
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2404087A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	CA2403425A1 Multivalent antibodies and uses therefor
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/18/2001	CA2401836A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	CA2400386A1 Anthelmintic combinations
10/17/2001	EP1145717A2 Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor
10/17/2001	EP1145644A2 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/17/2001	EP1145160A1 A global method for mapping property spaces
10/17/2001	EP1145011A2 Compositions and methods for the diagnosis and treatment of tumor
10/17/2001	EP1144686A2 Genetic predisposition to abnormal calcification conditions
10/17/2001	EP1144673A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
10/17/2001	EP1144652A1 Manipulating isoprenoid expression
10/17/2001	EP1144651A1 Polypeptides derived from jnk3
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144642A2 Compounds and methods for treatment and diagnosis of chlamydial infection

1 ... 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 ... 1151